Methods to identify Therapeutic Targets for the treatment of vulvovaginal atrophy

摘要

Refers to a Therapeutic Compound comprising an effector Molecule that modulates the activity of the receptors of the HIF (hypoxia inducible factor 1 alpha) or betacellulin, increasing HIF activity 1A, where the effector Molecule is selected from difenilalcanos (such as dimbenzoil Methane or substituted phenoxyacetic acids Carbamoyl) - or (as mersalil)Alquilico acid ester oxalamico (such as dimetiloxalil pyridines (Glycine), disustituidas dietilpiridina dicarboxilato); heteroaryl containing N of formula (i) (wo2004 / 4108681) being selected acid (7: 3 - Chloro - hydroxy quinoline - 2 - carbonyl) - amino] - 4 - oxo acetic acid - 1,4 - dihydro - [1,1 0] fenatrolina - 3 - acid,Among others, an siRNA that targets a PhD or FIH; noddd Peptide comprising the SEC ID no: 2; a Peptide comprising the coddd SEC ID no: 3; betacellulin Protein or a derivative or a Peptide comprising the betacellulin SEC ID no: 1; among others.It also relates to a method for identifying Target molecules for the treatment of vulvovaginal atrophy through genetic screening